Symptomatic Relief and Support for Digestive Comfort

This medication is commonly used across conditions presenting with acute diarrhoeal episodes, such as those arising from gastroenteritis (stomach infections) and food poisoning. It is applied when supportive symptom management is appropriate. This support helps manage symptoms that interfere with routine activities, like frequent, loose bowel movements. The therapy is also relevant for easing recurrent or episodic manifestations associated with the diarrhoea-dominant form of Irritable Bowel Syndrome (IBS-D). It is used for managing challenging symptom clusters, including abdominal pain, cramping, bloating, and defecation urgency. Furthermore, it plays a role in managing symptoms related to the overall toxic load and systemic imbalance that can arise when unwanted substances are present in the digestive tract.

Its application provides supportive relief: “It contributes to easing the overall symptom load and supports general well-being during symptomatic periods.”

Quick Fact: Support for Acute and Chronic Symptom Patterns
Common Acute Use	Acute Diarrhoeal Episodes (e.g., Gastroenteritis)
Relevant Chronic Use	Symptom Management in IBS-D (Diarrhoea, Pain, Bloating)
Key Benefit	Assisting with maintaining functional stability when symptoms are noticeable.

Who Can and Cannot Use Энтеросгель? (Official Regulatory Information)

Eligibility for Энтеросгель (Polymethylsiloxane Polyhydrate) is determined strictly by official regulatory labeling, focusing on specific health states and age groups.

---

Populations for Whom Use is Contraindicated

The medicine is absolutely contraindicated and must not be used by patients who have a diagnosis of intestinal blockage (mechanical obstruction) or intestinal atony (lack of normal bowel muscle tone). Use is also prohibited in individuals with known hypersensitivity or prior intolerance to the product.

---

Age and Life Stage Eligibility

Population Group	Eligibility Status
Infants/Children	Use is approved from birth; conditional use requires medical consultation for children under 3 years old.
Adults/Older Adults	Approved for standard use; no specific restrictions documented for older adults.
Pregnant/Lactating	Use is explicitly documented as acceptable during both pregnancy and breastfeeding.

---

Eligibility-Related Restrictions

The medicine is restricted for patients who are currently taking modified-release orally administered medications due to the risk of physical interference with drug absorption. Additionally, the product is not indicated for use in cases of severe acute chemical or medicinal overdose.

Interactions with other medicines and products

The officially documented interaction profile for Polymethylsiloxane Polyhydrate is entirely defined by its physical, non-systemic binding activity within the gastrointestinal tract. As an intestinal adsorbent, this medicine does not undergo systemic absorption and therefore has no documented interaction potential with hepatic cytochrome P450 enzymes or systemic drug transporters.

Documented Interaction Patterns

Classification	Official Regulatory Statement
Pharmacokinetic Interaction	Co-administration with any orally administered medicine may result in the reduction of that drug's systemic exposure (bioavailability).
Timing-Based Requirement	A mandatory rule requires administration at least two hours before or two hours after taking any other oral medicinal product.
Product Restriction	There is a formal restriction against concurrent use with oral modified-release medications due to the risk of interference with the formulation's designed absorption properties.
Co-Adsorbent Restriction	Caution is advised regarding the concomitant use with other oral intestinal adsorbents, such as activated charcoal or kaolin.
Substance Binding Profile	Regulatory-aligned information confirms a functional interaction with ingested materials, including the binding and removal of ethyl alcohol from the digestive tract.

This structure reflects the procedural constraints necessary to ensure that the medicine’s adsorptive action does not significantly alter the intended absorption of other oral medications, as defined by regulatory authorities.

How Enterosgel Works: Mechanism of Action

Enterosgel (Polymethylsiloxane Polyhydrate) functions as a purely peripheral intestinal adsorbent with a non-systemic mechanism of action. The drug’s rigid, porous hydrogel structure creates a high-surface-area environment strictly within the gastrointestinal (GI) lumen. The primary interaction is physical adsorption, where the gel selectively binds and sequesters medium- and high-molecular-weight compounds, including bacterial toxins, pathogens, and various metabolic waste products, thereby preventing their absorption through the intestinal wall.

This sequestration mechanism enhances the elimination pathway by stabilizing the drug-toxin complex for forced fecal excretion. Additionally, the compound forms a protective physical barrier that coats the intestinal epithelium, mitigating direct contact between the mucosal surface and luminal irritants. By binding metabolites typically subject to reabsorption, the mechanism effectively interrupts the enterohepatic cycling of toxins, resulting in attenuated systemic exposure to gut-derived compounds. The drug itself is not metabolized and exerts no direct agonistic, antagonistic, or inhibitory effects on host biological receptors or pathways.

Administration Route and Preparation

The Polymethylsiloxane Polyhydrate paste is administered exclusively via the oral route. The prescribed dose must be diluted in water at room temperature prior to ingestion. A critical administration instruction is to take the medicine 2 hours before or after the intake of any food or other oral medications. This separation is specified to maintain the medicine's activity and prevent interference with the absorption of other substances.

Official Dosing Regimens

The medicine is typically taken 3 times a day. The standard single dose for adults (15 years and older) ranges from 15 g to 22.5 g. For acute scenarios, the first day’s regimen is subject to an adjustment logic, permitting up to 8 doses. Dosing is strictly stratified for pediatric use, providing clear guidelines for younger patients. For example, children 7–14 years are administered 10 g 3 times a day, and infants under 1 year receive 2.5 g 3 times a day.

Duration and Treatment Cycles

Treatment duration is defined by the usage scenario, ranging from 3 to 5 days for acute episodes up to 30 days for chronic use. There is a break of at least 3 days before repeating a course for chronic administration, establishing a fixed cycle of use.

Research Evidence / Overview of Studies

---

Research on Substance Characteristics

Studies were designed to investigate an inhibitory effect on dual-pathways, including specific inflammatory biomarkers, exploring the substance's capacity to bind to toxins, bile acids, and other potentially harmful metabolites in the gut.

• Initial Research: Early preclinical studies focused on investigating the characteristics of the substance in relation to specific cellular markers. These in vitro (test tube) studies examined the relationship between the substance and possible physiological changes.
• Study Protocol & Participants: A large-scale, randomized, placebo-controlled trial (RCT) examined the substance in 440 adults diagnosed with Irritable Bowel Syndrome with Diarrhea (IBS-D).

---

Key Clinical Trial Outcomes

Research has primarily focused on the symptomatic management of acute diarrhea and IBS-D. The primary objective included the evaluation of participant outcomes compared to a placebo over an 8-week double-blind phase.

Symptom Management in IBS-D

Studies examined changes in abdominal pain and stool consistency. In the main RCT, a significantly higher percentage of participants in the substance group met the criteria for response to treatment (defined as a composite score for improvement in both abdominal pain and stool consistency) compared to the placebo group.

• Stool Consistency: Secondary endpoints included metrics related to changes in stool consistency and frequency, with greater reported improvement in the substance group.
• Abdominal Pain and Urgency: Trial data also recorded greater changes in abdominal pain, urgency, and bloating reports in the substance group compared to the placebo group.

Safety and Tolerability

• Adverse Events: The safety analysis for the IBS-D trial reported that the frequency of adverse events was similar between the substance group and the placebo group, with no serious adverse events attributed to the substance.
• Acute Diarrhea: A separate randomized controlled trial comparing the substance plus standard care (oral rehydration solution) to standard care alone, recorded a significantly shorter duration of diarrhea in the substance group in adults with acute diarrhea.

---

Formulation and Bioavailability

Research evaluated participant absorption metrics following the use of this specific combination. As an intestinal adsorbent, the substance is designed to pass through the gastrointestinal tract and be fully excreted from the body without being absorbed into the bloodstream. Information about these findings is available for review in the published literature.

Common questions about Энтеросгель (FAQ)

Q: What is the main mechanism of action of Энтеросгель?

A: Энтеросгель is described in regulatory documents as an intestinal adsorbent, meaning its primary function is to bind and remove toxic substances from the gut. It is designed to selectively absorb various toxins, allergens, metabolic waste products, and pathogens within the intestinal lumen. This process is described as assisting the body's natural processes by removing substances from the gut.

Q: What is the active ingredient in Энтеросгель?

A: The active substance in Энтеросгель is polymethylsiloxane polyhydrate. This compound is a porous organic silicon matrix that serves as the adsorbent material. According to the official product information, it is the structure of this active substance that enables the product to bind harmful substances within the digestive tract.

Q: Does Энтеросгель require a prescription?

A: Based on regulatory and product information, Энтеросгель is generally available as an over-the-counter (OTC) medicine. This means that, in most cases, a prescription is not required to purchase the product. However, availability and classification may vary depending on local pharmaceutical regulations.

Q: Can Энтеросгель be used for allergic conditions?

A: Official information indicates that one of the uses for Энтеросгель is for allergic diseases, including food and drug allergies. As an intestinal adsorbent, its function is based on removing substances like allergens from the gut, as part of the overall management strategy for these reactions.

Q: Is there a recommended period of time for continuous use of Энтеросгель?

A: The recommended duration of use for Энтеросгель varies depending on the condition being addressed. Official product instructions suggest that for acute conditions, the course of use may be shorter, typically days. For chronic diseases or severe intoxications, a longer course, often extending to weeks, may be necessary. The duration of use should align with the specific guidelines provided in the official regulatory documentation.

Q: Can Энтеросгель be taken with food?

A: Regulatory documents state that Энтеросгель should be taken separately from meals. Regulatory documents suggest separating the administration of the product from meals by 1–2 hours, as this timing is specified to support its action as an adsorbent.

Q: Is it okay to mix Энтеросгель with water or other liquids before taking it?

A: Yes, according to the official product information, Энтеросгель should be taken with a sufficient amount of water. For ease of use, the paste can be mixed into a small quantity of water before administration, or it can be taken orally followed immediately by a drink of water.

Q: Does Энтеросгель get absorbed into the bloodstream?

A: Regulatory sources indicate that Энтеросгель is not absorbed into the gastrointestinal lining or the bloodstream. Its mechanism of action is limited to the intestinal lumen, where it binds toxins. After its function is complete, the entire complex of the drug and bound substances is eliminated from the body within about 12 hours.

Q: Is Энтеросгель indicated for use in diarrhea?

A: Official product information lists acute and chronic diarrhea among the conditions for which Энтеросгель is indicated. The product's function as an intestinal adsorbent is to bind and remove substances from the gut that may contribute to diarrhea, according to its mechanism of action.

Q: How long does it take for Энтеросгель to start working?

A: Studies and official information indicate that Энтеросгель generally begins its adsorbing action relatively quickly after consumption. While the rate of effect can vary, the drug's use in acute settings suggests its action begins promptly within the digestive tract, as its mechanism is based on immediate physical adsorption.

Storage and Handling Requirements

Official regulatory labeling dictates that Enterosgel must be stored at a temperature between 4 °C and 30 °C. The product must not be frozen** and should be kept away from direct sunlight and heat.

For the tube formulation, the lid must be closed tightly after each use to avoid drying and prevent contamination. An opened tube must be used within 30 days. Sachets are for single use only and must be opened immediately before use.

Shelf-Life and Disposal

The medicine must be kept out of the reach of children.

The official shelf life for an unopened product is three years. The medicine should not be used after the expiry date. There are no special disposal requirements for unused or expired Enterosgel; it can be safely disposed of into the domestic waste.